The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...

Good day, and thank you for standing by. Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential successor to Wegovy (semaglutide), as the company aims to quell ...

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

Shares of Novo Nordisk (NYSE: NVO) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but gained as much as 5.8% earlier in the day. The leg up comes as the S&P ...

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 18 unusual trades. Delving into the details, we found 33 ...

The company is also grappling with competition from Eli Lilly. (Image Credits: PIxabay) Novo Nordisk on Wednesday announced that it plan to file its experimental next-generation obesity drug ...

Novo Nordisk’s annual results are out and they show the Danish pharmaceutical juggernaut earnt 290.4 billion Danish kroner last year (A$64 billion) — up 25%. Novo Nordisk boasts 45 million ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks. Ken Fisher is the founder and executive chairman of Fisher Asset Management ...